Abstract
Biallelic PRKN mutation carriers with Parkinson’s disease typically have an earlier disease onset, slow disease progression and, often, different neuropathology compared to sporadic patients. However, the role of heterozygous PRKN variants in the risk of Parkinson’s disease remains unclear. In the current study we examined the association between heterozygous PRKN variants, including single nucleotide variants and copy number variations, and Parkinson’s disease status. We fully sequenced PRKN in 2,807 Parkinson’s disease patients and 3,627 healthy controls, including 1,903 late onset (mean [Standard Deviation], 64.02±7.81 years, 1,196 men [63%]) and 542 early onset patients (mean [SD], 43.30±6.60, 368 men [68%]). PRKN was sequenced using targeted next-generation sequencing with molecular inversion probes. Copy number variations were identified using a combination of multiplex ligation-dependent probe amplification and the ExomeDepth tool. To examine whether rare heterozygous variants and copy number variations in PRKN are associated with Parkinson’s disease risk and onset, we used optimized sequence kernel association tests and regression models. We did not find any associations between all types of PRKN variants and risk of Parkinson’s disease. Pathogenic and likely pathogenic heterozygous variants and copy number variations were less common among Parkinson’s disease patients (1.0%) than among controls (1.3%, P=0.006, not statistically significant after correction for multiple comparisons). These results suggest that heterozygous variants and copy number variations in PRKN are not associated with Parkinson’s disease. Molecular inversion probes allow for rapid and cost-effective detection of all types of PRKN variants, which may be useful for pre-trial screening and for clinical and basic science studies specifically targeting PRKN patients.
- Abbreviations
- Age at onset
- :AAO
- American College of Medical Genetics and Genomics
- :ACMG
- Combined Annotation Dependent Depletion
- :CADD
- Copy number variation
- :CNV
- Early onset Parkinson’s disease
- :EOPD
- Genome Aggregation Database
- :GnomAD
- Late onset Parkinson’s disease
- :LOPD
- Minor allele frequency
- :MAF
- Molecular inversion probe
- :MIP
- Multiplex ligation-dependent probe amplification
- :MLPA
- Optimized sequence kernel association test
- :SKAT-O
- Quality control
- :QC
- Single nucleotide variants
- :SNV
Competing Interest Statement
Dr. Fahn received consulting fees/honoraria for board membership from Retrophin Inc., Sun Pharma Advanced Research Co., LTD and Kashiv Pharma. Dr. Waters received research support from Sanofi, Biogen, Roche, consulting fees/honoraria from Amneal, Adamas, Impel, Kyowa, Mitsubishi, Neurocrine, US World Meds, Acadia, Acorda. Dr. Espay received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, Neurocrine, Impax/Amneal, Sunovion, Lundbeck, Osmotica Pharmaceutical, and US World Meds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from US World Meds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the Movement Disorders Society. Dr. Dupré received consultancy fees from Actelion Pharmaceuticals. Dr. Hassin-Baer received consulting fees from Actelion Pharmaceuticals Ltd., Abbvie Israel, Robotico Ltd., Medtronic Israel, Medison Pharma Israel. Dr. Fon received consulting fees from Inception Sciences. Dr. Alcalay received consultation fees from Biogen, Denali, Genzyme/Sanofi and Roche. Dr. Gan-Or received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali and Deerfield. No other disclosures were reported.
Funding Statement
Funding/Support
This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson’s Foundation, the National Institutes of Health (K02NS080915, and UL1 TR000040) and the Brookdale Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.
